Objective To investigate the efficacy and safety of dagliprazin combined with irbesartan in the treatment of patients with early diabetic nephropathy(DN).Methods A total of 84 patients with early DN admitted to the Depart-ment of Internal Medicine,Jiangyin Changjing Hospital from January 2022 to March 2024 were selected as the re-search objects.According to different treatment methods,they were divided into observation group and control group,with 42 cases in each group.On the basis of routine life intervention and hypoglycemic therapy,the control group was treated with irbesartan orally,and the observation group was treated with dapagliflozin combined with irbesartan orally.The inflammatory stress indexes,glucose and lipid metabolism indexes,renal function indexes,clinical efficacy and adverse reactions were compared between the two groups.Results After treatment,the levels of inflammatory stress indexes(hypersensitive C-reactive protein,cystatin C and homocysteine)in the two groups were lower than those before treatment,and those in the observation group were lower than the control group,the differences were sta-tistically significant(all P<0.05).After treatment,the levels of glycated hemoglobin A1c,fasting plasma glucose,2-hour postprandial plasma glucose,total cholesterol and triglyceride in both groups were lower than before treatment,and level of the C-peptide was higher than that before treatment,and the improvement of each indexes in the observa-tion group were better than those in the control group,and the differences were statistically significant(all P<0.05).Af-ter treatment,the levels of renal function indexes(blood urea nitrogen,creatinine and β2-microglobulin)in the two groups were lower than those before treatment,and those in the observation group were lower than the control group,the differences were statistically significant(all P<0.05).The total effective rate of treatment in the observation group was 95.24%(40/42),which was higher than 83.33%(35/42)in the control group,and the difference was statistically significant(χ2=3.495,P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of daglipzin and irbesartan in the treatment of early DN patients can effectively reduce the inflammatory stress state of the body,regulate the disorder of glucose and lipid metabolism,improve kidney function,improve treatment effect,and have high drug safety.
Diabetic nephropathyDaglizinIrbesartanInflammatory stressRenal function
维普
万方数据
